Please login to the form below

Not currently logged in
Email:
Password:

Syncona

This page shows the latest Syncona news and features for those working in and with pharma, biotech and healthcare.

Novartis and Syncona back new Swiss biotech Anaveon

Novartis and Syncona back new Swiss biotech Anaveon

Founders focused on IL-2 Receptor Agonists. Novartis' venture fund arm and Syncona are supporting new Switzerland-based immuno-oncology specialists Anaveon. ... Syncona is the venture funding group driving a lot of gene therapy and immuno-oncology

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • European venture funding for the life science sector European venture funding for the life science sector

    New funds such as Oxford Sciences Innovation, Syncona (which listed at the start of the year and consequently increased its deployment capital) are likely to reinforce this trend going forward. ... The recent flotation of Syncona’s Nightstar

  • Pharma deals during January 2013 Pharma deals during January 2013

    in this vein this year, the Wellcome Trust announced the investment of $200m initial capital into Syncona Partners LLP a new evergreen investment company. Syncona will make investments across healthcare – device, ... Acquisition. Contraception

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    team. Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Chris Hollowood, chairman of Freeline Therapeutics and chief investment officer of Syncona, said: “Anne is an extremely accomplished executive with extensive experience in building and leading teams and developing haematology and

  • Edward Hodgkin elected chair of UK biotech association Edward Hodgkin elected chair of UK biotech association

    Hodgkin is currently a partner at the Wellcome Trust's independent subsidiary Syncona Partners, where his role is to create and lead new life science ventures.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics